LeMaitre (NASDAQ: LMAT) CFO exercises dividend rights and uses shares for taxes

Rhea-AI Filing Summary

LeMaitre Vascular’s Chief Financial Officer Dorian Paul LeBlanc reported routine equity compensation activity. On March 10, 2026, he exercised dividend equivalent rights into 2 shares of common stock at $0.00 per share and now holds 9.3269 dividend equivalent rights. He also holds 2,302 shares of common stock directly after these transactions.

The filing shows 96 shares of common stock were withheld at $109.20 per share to satisfy tax obligations on restricted stock units that vested from an award granted on March 10, 2025. The tax withholding is characterized as an exempt sale under Rule 16b-3(e) and does not reflect an open-market trade.

Insider Trade Summary

2 shares exercised/converted

Mixed 3 txns

Insider LeBlanc Dorian Paul

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Exercise	Dividend Equivalent Rights	2	$0.00	--
Exercise	Common Stock	2	$0.00	--
Tax Withholding	Common Stock	96	$109.20	$10K

Holdings After Transaction: Dividend Equivalent Rights — 9.327 shares (Direct); Common Stock — 2,400 shares (Direct)

Footnotes (1)

1. Represents shares acquired upon release of dividend equivalent rights, as reported in Table II, on a one-for-one basis. These shares represent shares withheld by the Issuer to satisfy tax withholding obligations incurred upon the vesting of restricted stock units awarded to the reporting person on March 10, 2025. This transaction is considered an exempt sale pursuant to Rule 16b-3(e) promulgated under the Securities Exchange Act of 1934. These dividend equivalent rights were released in connection with the vesting of a restricted stock unit award granted on March 10, 2025. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

LeBlanc Dorian Paul

(Last) (First) (Middle)

C/O LEMAITRE VASCULAR, INC.

63 SECOND AVENUE

(Street)

BURLINGTON MA 01803

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
LEMAITRE VASCULAR INC [ LMAT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/10/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/10/2026		M		2(1)	A	$0(1)	2,400	D
Common Stock	03/10/2026		F		96(2)	D	$109.2	2,302	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Dividend Equivalent Rights	(3)	03/10/2026		M			2(3)	(3)	(3)	Common Stock	2	$0	9.3269	D

Explanation of Responses:

1. Represents shares acquired upon release of dividend equivalent rights, as reported in Table II, on a one-for-one basis.

2. These shares represent shares withheld by the Issuer to satisfy tax withholding obligations incurred upon the vesting of restricted stock units awarded to the reporting person on March 10, 2025. This transaction is considered an exempt sale pursuant to Rule 16b-3(e) promulgated under the Securities Exchange Act of 1934.

3. These dividend equivalent rights were released in connection with the vesting of a restricted stock unit award granted on March 10, 2025. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.

	/s/ Laurie A. Churchill, Attorney-in-fact	03/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did LeMaitre Vascular (LMAT) CFO report?

LeMaitre Vascular’s CFO reported exercising dividend equivalent rights into 2 common shares and a tax-related share withholding of 96 shares. These events stem from equity compensation vesting rather than open-market buying or selling of LMAT stock.

How many LeMaitre Vascular (LMAT) shares does the CFO hold after the filing?

After these transactions, the CFO directly holds 2,302 shares of LeMaitre Vascular common stock. He also holds 9.3269 dividend equivalent rights, each economically equivalent to one share of common stock, reflecting ongoing equity-based compensation.

Why were 96 LMAT shares disposed of in the CFO’s Form 4?

The 96 LMAT shares were withheld by the company to cover tax obligations when restricted stock units vested from a March 10, 2025 award. This withholding is treated as an exempt sale under Rule 16b-3(e), not an open-market stock sale.

What are dividend equivalent rights in the LeMaitre Vascular (LMAT) Form 4?

Dividend equivalent rights are compensation instruments economically equivalent to common shares. In this filing, 2 dividend equivalent rights converted into 2 shares of LMAT common stock, and remaining rights total 9.3269, aligning with the vesting of a prior restricted stock unit award.

Did the LeMaitre Vascular (LMAT) CFO buy or sell shares on the open market?

No open-market purchases or sales are reported. The filing shows a derivative exercise of dividend equivalent rights and a tax withholding disposition of 96 shares tied to restricted stock unit vesting, both routine equity compensation-related transactions.

What price was used for the LMAT tax withholding shares in the Form 4?

The 96 shares withheld for taxes were valued at $109.20 per share. This price is used to calculate the tax withholding on the vesting restricted stock units, and does not represent an open-market trade initiated by the CFO.